Peanut allergy patch: a new hope for kids?

NCT ID NCT01197053

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 21, 2026 · Last updated Aug 21, 2026

Summary

This trial tests whether a skin patch delivering peanut proteins can safely desensitize children with peanut allergy. Children aged 5 to 17 will wear the patch daily for six months, and researchers will check if they can eat more peanut without symptoms. The goal is to see if this approach can reduce the risk of severe reactions.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Epicutaneous immunotherapy with peanut proteins applied as a skin patch
What this could lead to
If successful, this could offer a practical, needle-free way to reduce peanut allergy reactions in children, potentially lowering the risk of severe reactions from accidental exposure.
What could go wrong
This is an early-phase pilot study with a small number of participants. The patch may not work for everyone, and there is a risk of skin irritation or allergic reactions at the application site.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

60 people

The number who actually took part.

Start date

Aug 2010

Finished

Apr 2015

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

5 to 17 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or Female between 5 and 17 years of age at enrollment * An efficient contraceptive method for girls with childbearing potential. Acceptable methods include sexual abstinence, oral, injectable contraceptive methods, intra uterine device. * Negative pregnancy test for girls with childbearing potential. * Child with a documented allergy to peanut, i.e. with peanut-specific IgE (\>5KU/L, ImmunoCAP method) and/or a positive skin prick test to peanut (wheal diameter ≥ 8mm). * Child able to consume a cumulated quantity of peanut proteins \<250 mg during the baseline DBPCFC. * Child and his/her legal representative(s) who provide a signed consent form and assent form. * Child and his/her legal representative(s) whose family and social conditions allow them to understand the protocol and agree to comply in the long term with all study requirements. Exclusion criteria : * Child considered too severely allergic to peanut: with a history of severe anaphylaxis to peanut (with hypotension, loss of consciousness, severe bradycardia, respiratory or cardiac arrest requiring an admission to emergency rooms). * Child with peanut-specific IgE\<5 KU/L and whose skin prick test to peanut gave a wheal diameter \<8mm). * Child participating or having participated in a therapeutic study in the last 3 months * Pregnancy or Breastfeeding * Child with a generalized eczema * Child with an immune deficiency * Diabetic child * Child allergic to chocolate * Child or legal representative(s) who did not sign their consent or assent * Child with no baseline DBPCFC * Child having reacted to placebo during the baseline DBPCFC * Child able to consume \> 250 mg of cumulated peanut proteins during the baseline DBPCFC * Child with a respiratory deficiency or with an uncontrolled asthma. * Child who could not discontinue oral or I.V. antihistamines or oral or I.V. corticosteroids at least the week prior to Visit 1. * Child with important skin lesions precluding the application of the disks. * Child not affiliated to social security.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Peanut allergy are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

food allergy Peanut Hypersensitivity

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Hopital Necker

    Paris, 75015, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.